Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

01 Nov, 2018, 13:43 GMT Oncopeptides to Present Updated Data From the Two Ongoing Trials ANCHOR and HORIZON in Patients with RRMM at ASH in December 2018

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the abstracts for the 60th American Society of Hematology (ASH) meeting (December...


01 Nov, 2018, 13:41 GMT Nordic Nanovector: Promising Results from Preclinical Studies with a Novel CD37-targeted Alpha Therapy for B-cell Tumours to be Presented at ASH

Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting promising results from a research collaboration to develop a novel...


31 Oct, 2018, 12:57 GMT Medasense Announces Positive Results From Clinical Outcome Studies Using the NOL® Monitoring Technology for Optimized Pain Control

The leading study, investigating NOL-guided opioid administration, demonstrated that using the NOL technology significantly reduced...


31 Oct, 2018, 12:42 GMT OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD

OxThera AB, a Stockholm-based privately-held biopharmaceutical company and leader in the field of microbiome derived biotherapeutics, today announced ...


31 Oct, 2018, 11:18 GMT Nurofen and Pain UK Mobilise 24 People, That Suffered From Body Pain, to Help Build a Pop-Up Body Garden in 24 Hours and Showcase What Can be Achieved When Not Held Back by Pain

Almost 10 million Britons suffer from pain most days resulting in a major impact on their quality of life and more days off work[1] The pain barrier...


30 Oct, 2018, 15:54 GMT Arix Bioscience plc - Aura Biosciences Reports Positive Phase 1b/2 Clinical Data for AU-011

Multiple doses of AU-011 are well tolerated, with vision preservation observed at 12 to 18 months All Patients met preliminary efficacy endpoint to...


30 Oct, 2018, 13:12 GMT Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144

Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed...


30 Oct, 2018, 12:00 GMT Asthma+me Self-care Solution for Children and Young People With Asthma, Launched by Aseptika (Activ8rlives)

1.1 million children in the UK have Asthma. During 2015-2016, 21 children died from asthma attacks. It was reported that 19 of these deaths could...


29 Oct, 2018, 15:31 GMT AMO Pharma Reports Positive Data from Investigator-Led TIDE Study of AMO-02 in Autism Spectrum Disorder

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited...


29 Oct, 2018, 10:00 GMT Progress Update on GDC-0084 Program

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an update to...


27 Oct, 2018, 20:00 BST Bluegrass Vascular Announces Positive Results From Independent Study Building On Growing Body Of Evidence For Clinical Application Of The Surfacer System

Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for...


27 Oct, 2018, 08:30 BST Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

Presenting the study results, Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program confirmed that the analysis of...


26 Oct, 2018, 08:00 BST Alcohol-related Disorders: Ethypharm Is Granted Marketing Authorisation for Its Drug Baclocur®

World first The National Agency for the Safety of Medicines and Healthcare Products (ANSM) has just granted Ethypharm marketing authorisation for its ...


26 Oct, 2018, 06:17 BST Nordic Nanovector Announces Opening of First US Site for PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma

Nordic Nanovector ASA (OSE: NANO) announces that the first clinical site in the United States (in Long Beach, CA) for the pivotal PARADIGME trial has ...


25 Oct, 2018, 21:15 BST CartiHeal Performs the 100th Agili-C™ Implant Procedure in Italy in the Company's IDE Multinational Pivotal Study

CartiHeal, developer of the proprietary Agili-C implant for the treatment of joint surface lesions, and the Principal Investigator Professor...


25 Oct, 2018, 19:09 BST BERG Presents New Research Using AI and Multi-Omics Toward Identification of Multiple Clinical Outcome Biomarkers for Systemic Lupus Erythematosus at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, yesterday presented findings...


25 Oct, 2018, 17:57 BST Arix Bioscience plc - Arix to Host Oncology KOL Event on October 30, 2018

Webcast to begin at 12:00pm ET Focus on recent developments in synthetic lethality and bi-specific antibodies within oncology Arix Bioscience plc...


25 Oct, 2018, 13:47 BST BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) previously announced on July 6, 2018 the positive topline results from the clinical Phase 2b study...


25 Oct, 2018, 13:00 BST Daiichi Sankyo Announces Clinical Research Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate [Fam-] Trastuzumab Deruxtecan (DS-8201) with Avelumab and a DNA Damage Response Inhibitor in Patients with HER2 Expressing and Mutated Solid Tumors

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration agreement with Merck...


25 Oct, 2018, 08:15 BST Novel Drug Treatment Shows Improved Cognition in a Phase 3 Clinical Trial in Persons with Mild-to-Moderate Alzheimer's Disease in China

Green Valley Pharmaceutical Co., Ltd. (Headquarter: Shanghai) announced promising findings from a Phase 3 clinical trial of GV-971, a multi targeting ...


23 Oct, 2018, 15:47 BST AMO Therapeutics Announces Presentation of Concordant Analysis of Results of Phase 2 Study of AMO-02 in treatment of myotonic dystrophy

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating diseases with limited or no treatment...


23 Oct, 2018, 14:22 BST COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression

COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received...


23 Oct, 2018, 13:00 BST GenePOC® Launches its GenePOC® CDiff Test in Canada

GenePOC announces the Health Canada approval and launch of its molecular diagnostic test for the detection of Clostridium difficile in Canada GenePOC ...


23 Oct, 2018, 07:36 BST Cyxone Selects First Clinical Site Ahead of Phase 1 Study With T20K in MS

Cyxone AB (publ) announced today that the company has selected the clinical site that will carry out the drug candidate T20K's first in man study....


23 Oct, 2018, 07:00 BST Enterome Signs Global Licensing, Co-development and Co-promotion Agreement with Takeda for the Treatment of Crohn's Disease

EB8018, the lead investigational candidate, targets Crohn's disease with potential for other GI disorders ENTEROME SA, a clinical-stage biotech...